ReviewCancer management and research2021

Playing the Devil's Advocate: Should We Give a Second Chance to mTOR Inhibition in Renal Clear Cell Carcinoma? - ie Strategies to Revert Resistance to mTOR Inhibitors.

Gaetano Pezzicoli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.